Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety
16 juin 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results
04 mai 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
- Company records $59.4 million in total net product sales -
- JUXTAPID® net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first quarter of 2014...
Aegerion Pharmaceuticals Observes Rare Disease Day
28 févr. 2015 07h15 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results
26 févr. 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
- Company records $158.4 million in net product sales of JUXTAPID® in 2014, representing 226% growth over 2013 -
- Company generates $17.9 million in positive cash flow from operations in the...
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference
25 févr. 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
09 avr. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules Approved in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
10 févr. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
20 janv. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 20, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results
06 mars 2013 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results
06 janv. 2012 12h57 HE
|
Aegerion Pharmaceuticals, Inc.
Efficacy and Safety Profile Maintained
Company to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Aegerion...